Nothing Special   »   [go: up one dir, main page]

EP1007714A1 - Regulatorische sequenzen für die in-vivo-expressioneiner heterologen dns-sequenz in endothelzellen und ihre verwendungen. - Google Patents

Regulatorische sequenzen für die in-vivo-expressioneiner heterologen dns-sequenz in endothelzellen und ihre verwendungen.

Info

Publication number
EP1007714A1
EP1007714A1 EP98934910A EP98934910A EP1007714A1 EP 1007714 A1 EP1007714 A1 EP 1007714A1 EP 98934910 A EP98934910 A EP 98934910A EP 98934910 A EP98934910 A EP 98934910A EP 1007714 A1 EP1007714 A1 EP 1007714A1
Authority
EP
European Patent Office
Prior art keywords
gene
expression
flk
recombinant dna
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP98934910A
Other languages
English (en)
French (fr)
Other versions
EP1007714B1 (de
Inventor
Georg Breier
Werner Risau
Volker RÖNICKE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority to EP98934910A priority Critical patent/EP1007714B1/de
Publication of EP1007714A1 publication Critical patent/EP1007714A1/de
Application granted granted Critical
Publication of EP1007714B1 publication Critical patent/EP1007714B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Definitions

  • the present invention relates to recombinant DNA molecules comprising the regulatory sequence(s) of an intron of the Vascular Endothelial Growth Factor (VEGF) receptor-2 gene (Flk-1) or of a gene homologous to the Flk-1 gene, being capable of conferring expression of a heterologous DNA sequence in endothelial cells in vivo.
  • VEGF Vascular Endothelial Growth Factor
  • the present invention also relates to vectors comprising said recombinant DNA molecules as well as to host cells transformed with such recombinant DNA molecules or vectors.
  • the present invention additionally relates to pharmaceutical and diagnostic compositions comprising such recombinant DNA molecules, vectors or cells.
  • the present invention relates to cells and transgenic non-human animals, comprising the aforementioned recombinant DNA molecules or vectors stably integrated into their genome and their use for the identification of substances capable of suppressing or activating transcription of a gene in endothelial cells.
  • the present invention also relates to the use of the before described recombinant DNA molecules and vectors for the preparation of pharmaceutical compositions for treating, preventing, and/or delaying a vascular or tumorous disease in a subject.
  • the recombinant DNA molecules and vectors of the invention can be used for the preparation of pharmaceutical compositions for inducing a vascular or tumorous disease in a non-human animal.
  • the Kinase-insert Domain-containing Receptor/fetal liver kinase-1 (KDR/Flk-1 ) in the following referred to as Flk-1 and Flt-1 are high affinity signaling receptors for the endothelial mitogen, vascular endothelial growth factor (VEGF) (Connolly, J. Clin. invest. 84 (1989), 1470-1478; Leung, Science 246 (1989), 1306-1309). Through interactions with its receptors, VEGF plays critical roles in growth and maintenance of vascular endothelial cells and in the development of new blood vessels in physiologic and pathologic states (Aiello, New Engl. J. Med.
  • VEGF vascular endothelial growth factor
  • VEGF vascular endothelial growth factor
  • Flk-1 is expressed in endothelial cells at all stages of development, as well as in the blood island in which endothelial cell precursors first appear (Millauer, Cell 72 (1993), 835-846). Flk-1 is a marker for endothelial cell precursors at their earliest stages of development (Yamaguchi, Development 118 (1993), 489-498).
  • the vascular endothelium is critical for physiologic responses including thrombosis and thrombolysis, lymphocyte and macrophage homing, modulation of the immune response, and regulation of vascular tone.
  • the endothelium is also intimately involved in the pathogenesis of vascular diseases such as atherosclerosis (Ross, Nature 362 (1993), 801-809).
  • atherosclerosis Ross, Nature 362 (1993), 801-809
  • a number of genes expressed in the endothelium have been characterized (Collins, J. Biol. Chem. 266 (1991 ), 2466- 2473; lademarco, J. Biol. Chem. 267 (1992), 16323-16329; Gonzoudi, Mol. Cell. Biol. 14 (1994), 999-1008; Lee, J. Biol.
  • vascular endothelium e.g., the genes encoding von Willebrand factor, endothelin-1 , vascular cell adhesion molecule-1
  • Flk-1 also known as VEGF-receptor 2
  • the Flk-1 receptor is the first endothelial receptor to be expressed in endothelial cell precursors during embryonic vascular development.
  • the technical problem of the present invention is to provide means and methods that allow the modulation of gene expression specifically in endothelial cells in vivo, preferably at all stages of development.
  • the invention relates to a recombinant DNA molecule comprising:
  • VEGF Vascular Endothelial Growth factor
  • Flk-1 Vascular Endothelial Growth factor receptor-2
  • a regulatory sequence driving the expression of a heterologous DNA sequence in substantially all endothelial cells in vivo, preferably at substantially all stages of development has been identified.
  • Said regulatory sequence is suitable to direct the expression of a heterologous DNA sequence in the above-mentioned cells.
  • the recombinant DNA molecule of the invention allows studying the function and interaction of proteins which are expressed in the endothelium of, for example, humans and the malfunction, and/or unregulated expression of which is supposed to be the or a causative agent of vascular and tumorous diseases.
  • the regulatory sequences of the invention are particularly suited and useful for the engineering of transgenic cells and non- human animals which can serve as a test system for the development of drugs for the treatment of vascular and tumorous diseases of endothelial origin.
  • a first regulatory sequence of an intron of the Flk-1 gene means a nucleotide sequence of the first intron of the murine Flk-1 gene including the regulatory sequences which are capable of conferring the specific expression of a heterologous DNA sequence in endothelial cells, preferably at all stages of development.
  • the high affinity receptor for vascular endothelial growth factor (VEGF), Flk-1 is the first endothelial receptor to be expressed in angioblast precursors, and its function is essential for the differentiation of the hemangioblastic lineage.
  • VEGF vascular endothelial growth factor
  • Flk-1 vascular endothelial growth factor
  • cis-acting regulatory elements of the murine Flk-1 gene have been identified that mediate endothelial specific expression of a reporter gene in transgenic mice. Sequences within the 5 ' -flanking region of the Flk-1 gene, in combination with sequences located in the first intron, specifically and reproducibly targeted transgene expression to endothelial cells of the embryonic vasculature.
  • the regulatory sequences located in the first intron also functioned as an autonomous endothelium-specific enhancer when fused to the heterologous herpes simplex virus-thymidine kinase promoter.
  • This Flk-1 intron enhancer contains several potential binding sites for transcription factors of the Ets and GATA families. Sequences of the Flk-1 promoter contributed to a strong, complete and reproducible endothelial cell-specific gene expression in the embryo and are essential for expression in the yolk sac.
  • recombinant bacteriophage lambda clones containing mouse genomic DNA (Mouse strain 129/Sv) have been isolated encompassing a 21 kilo base pair (kb) region of the mouse Flk-1 gene, contained in the DNA insertions of ⁇ phages 6 and 16, including approximately 15 kb of 5' flanking sequences, exons 1 , 2 and 3, and introns 1 and 2 (Fig. 4A).
  • the DNA sequence of a 12.8 kb region spanning from position -6.65 kb (the affixes - and + refer to the nucleotide position relative to the transcriptional start site as shown in Fig.
  • the first intron (nucleotides 7027 to 10642 of SEQ ID NO: 1 ) of the mouse Flk-1 gene is essential for endothelium specific gene expression.
  • a DNA fragment (see Figure 12) comprising nucleotides 10094 to 10608 of SEQ ID NO: 1 was shown in accordance with the present invention to be sufficient to direct the expression of a heterologous DNA sequence into endothelial cells; see Example 8. This is a novel finding because the sequences described in previous publications (Patterson, supra; Ronicke, supra) are, in contrast to the expectations and interpretations of the prior art, not sufficient to mediate endothelium-specific expression in vivo.
  • the genomic DNA of the murine Flk-1 gene comprising the intron regulatory sequences can be obtained from liver of mouse strain 129/SV, or, for example, by screening a phage library of liver genomic DNA in the vector ⁇ Fixll (Stratagene, La Jolla, CA) generated by conventional methods known in the art.
  • regulatory sequence of a gene homologous to the Flk-1 gene also includes promoter regions and regulatory sequences of a gene from another species, for example, humans and other mammals which is homologous to the Flk-1 gene of mouse and which confers the same or substantially the same expression pattern.
  • Such regulatory sequences are characterized by their capability of conferring expression of a heterologous DNA sequence specifically in endothelial cells in vivo, preferably at all stages of development.
  • regulatory sequences from other species can be used that are functionally homologous to the regulatory sequences of the intron of the Flk-1 gene from mouse, or regulatory sequences of genes that display a substantially identical pattern of expression, in the sense of being expressed in the endothelium, preferably at all stages of development.
  • Flk-1 gene from mouse, corresponding genes from other species, for example, humans and other mammals. This can be done by conventional techniques known in the art, for example, by using Flk-1 gene sequences as a hybridization probe or by designing appropriate PCR primers. It is then possible to isolate the corresponding regulatory sequences by conventional techniques and test them for their expression pattern. For this purpose, it is, for instance, possible to fuse the regulatory sequences to a reporter gene, such as the luciferase or green fluorescent protein (GFP) encoding genes and assess the expression of the reporter gene in transgenic animals, for example in mice.
  • the partial nucleotide sequence of the human Flk-1 gene may be obtained from Genbank Ace. No.
  • the present invention also relates to recombinant DNA molecules comprising regulatory sequences which are substantially identical to that of the Flk-1 intron or to an intron of a homologous gene or to fragments thereof and which are able to confer specific expression in endothelial cells, preferably at all stages of development in mouse or other mammals.
  • Such regulatory sequences differ at one or more positions from the above- mentioned regulatory sequences but still have the same specificity, namely they comprise the same or similar sequence motifs responsible for the above described expression pattern.
  • Preferably such regulatory sequences hybridize to one of the above-mentioned regulatory sequences, most preferably under stringent conditions.
  • Particularly preferred are regulatory sequences which share at least 85%, more preferably 90-95%, and most preferably 96-99% sequence identity with one of the above-mentioned regulatory sequences and have the same specificity.
  • Such regulatory sequences also comprise those which are analogues or derivatives, for example by way of nucleotide deletion(s), insertion(s), substitution(s), addition(s), and/or recombination(s) and/or any other modification(s) known in the art either alone or in combination in comparison to the above-described nucleotide sequence.
  • Methods for introducing such modifications in the nucleotide sequence of the regulatory sequences of the invention are well known to the person skilled in the art and described, for example, in Sambrook (Molecular cloning; A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY (1989)).
  • regulatory sequences of the invention are included within the scope of the present invention, as long as the essential characteristic regulatory properties as defined above remain unaffected in kind. It is also immediately evident to the person skilled in the art that further regulatory sequences may be added to the regulatory sequences of the invention.
  • promoters, transcriptional enhancers and/or sequences which allow for induced expression of the regulatory sequences of the invention may be employed.
  • a suitable inducible system is for example tetracycline-regulated gene expression which is described by, e.g., Gossen (Proc. Natl. Acad. Sci. USA 89 (1992), 5547- 5551 ; Trends Biotech. 12 (1994), 58-62).
  • the expression conferred by the regulatory sequences of the invention may not be exclusively limited to the above-described specificity but may also occur in, e.g., neuronal cells, including neural retinal progenitor cells at all or different stages of development and haematopoietic cells (Yang, J. Neurosci. 16 (1996), 6089-6099).
  • flanking regulatory sequences refers to sequences which influence the specificity and/or level of expression, for example in the sense that they confer cell and/or tissue specificity or developmentally and/or inducible regulated gene expression. Such regions can be located upstream of or comprising the transcription initiation site, such as a promoter, but can also be located downstream of it, e.g., in transcribed but not translated leader sequences.
  • promoter refers to the nucleotide sequences necessary for transcription initiation, i.e. RNA polymerase binding, and also includes, for example, the TATA box.
  • in vivo for the purpose of the present invention is used for cells in an organism as opposed to cells growing in culture (in vitro).
  • heterologous with respect to the DNA sequence being operatively linked to the promoter of the invention means that said DNA sequence is not naturally linked to the regulatory sequences comprised in the recombinant DNA molecule of the invention.
  • said first regulatory sequence of the invention comprises a GATA-binding site, an AP-1 binding site, an SP1 binding site, site, an NFKB binding site, a STAT binding site, a Scl/Tal-1 binding site, an Ets-1 binding site, a PEA3 consensus sequence or any combination(s) thereof.
  • a functional analysis of the first 6.5 kbp of the transcribed region of the murine Flk-1 genes lead to the identification of a endothelial-specific positive regulatory element. This regulatory sequence is located in the region between the Xhol and BamHI restriction site in the first intron of the Flk-1 gene (cf. Fig. 4A).
  • c-ets1 10094 to 10608 of SEQ ID NO: 1 ).
  • PEA3 an Ets-Iike transcription factor
  • GATA transcription factors Several potential binding sites for known transcription factors could be identified therein (see Figure 12), including consensus binding sites for c-ets1 , PEA3 (an Ets-Iike transcription factor), GATA transcription factors, and Scl/Tal-1.
  • the c-ets1 transcription factor was proposed to be involved in the early differentiation of endothelial cells from their precursors (Pardanaut Cell
  • c-ets1 is expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans (Wernert, Am. J. Pathol. 140 (1992), 119-127). Proteins of the Ets family can activate transcription through a PEA3 motif (Wernert, 1992). Transcription factors of the GATA family are involved in the transcription of genes that are expressed in the hematopoietic and endothelial lineages, such as von Willebrand factor (Roboudi, Mol. Cell. Biol. 14 (1994), 999-1008).
  • GATA-2 is expressed in both the endothelial and hematopoietic lineages (Elefanty, Blood 90 (1997), 1435-1447). Scl/Tal-1 has recently been implicated in the regulation of Flk-1 expression in Zebrafish (Liao,
  • said first regulatory sequence is selected from the group consisting of (a) DNA sequences comprising a nucleotide sequence as given in SEQ ID NO: 1 ;
  • DNA sequences comprising a nucleotide sequence of SEQ ID NO: 1 from nucleotide 8260 to nucleotide 10560, from nucleotide 8336 to nucleotide 10608 and/or from nucleotide 10094 to nucleotide 10608;
  • DNA sequences comprising a nucleotide sequence which hybridizes with a nucleotide sequence of (a), (b) or (c) under stringent conditions;
  • DNA sequences comprising a fragment, analogue or derivative of a nucleotide sequence of any one of (a) to (e) capable of conferring expression in endothelial cells.
  • the regulatory sequences comprise the nucleotides 8260 to 10560, 8336 to 10608 (comprising the BamHI/Xhol fragment of the first intron (+1677 bp/+3947); see Figure 4 and Examples 1 to 10), most preferably nucleotides 8560 to 10400 and still more preferably nucleotides 10094 to 10608 (comprising the Swal/BamHl fragment (+3437 bp/3947 bp); see Example 8) of the nucleotide sequence as set forth in SEQ ID No. 1 or a fragment thereof, which still confers expression in endothelial cells, preferably at all stages of development.
  • the heterologous DNA sequence of the recombinant DNA molecules described above is operatively linked to further regulatory sequences.
  • Expression comprises transcription of the nucleic acid molecule, preferably into a translatable mRNA.
  • Regulatory elements ensuring expression in eukaryotic cells, preferably mammalian cells, are well known to those skilled in the art. They normally comprise promoters ensuring initiation of transcription and optionally poly-A signals ensuring termination of transcription and stabilization of the transcript. Additional regulatory elements may include transcriptional as well as translational enhancers.
  • said further regulatory sequence is a promoter and/or a 3'-untranslated region.
  • endothelial-specific promoters have been characterized, e.g. of the genes for von Willebrand factor (Roboudi, Mol. Cell Biol. 14 (1994), 999-1008), Endothelin-1 (Lee, J. Biol. Chem. 265 (1990), 10446-10450), E-selectin (Collins, J. Biol. Chem. 266 (1991 ), 2466-2473), Tie-2 (Schlaeger, Development 121 (1995), 1089-1098), VCAM-1 (lademarco, J. Biol. Chem. 267 (1992), 16323-16329) and endothelial NO-synthase (Zhang, J. Biol. Chem.
  • these genes are neither specific for proliferating endothelium, nor necessary for endothelial cell determination. Due to the present invention these promoters can now be combined with the regulatory sequences of the invention in order to mediate endothelium specific gene expression of heterologous DNA sequences. However, other promoters can be used as well. For example, it is shown in Example 8 that the regulatory sequences of the invention conferred endothelium-specific gene expression to the heterologous herpes simplex virus-thymidine kinase (tk) promoter.
  • tk heterologous herpes simplex virus-thymidine kinase
  • the above mentioned promoter is a promoter of hypoxia inducible genes, genes encoding growth factors such as VEGF, PDGF or Fibroblast growth factor or their receptors or giycolytic enzymes.
  • DNA sequences comprising a nucleotide sequence which hybridizes with a nucleotide sequence of (a) or (b) under stringent conditions;
  • DNA sequences comprising a nucleotide sequence which is conserved in the nucleotide sequences of (a) and (b); and (e) DNA sequences comprising a fragment, analogue or derivative of a nucleotide sequence of any one of (a) to (d).
  • At least one of the aforedescribed DNA sequences may be preferably of human or murine origin although other sources may be employed as well.
  • the heterologous DNA sequence being operatively linked to the regulatory sequences is located 5' to the regulatory sequence of the invention.
  • the heterologous DNA sequence of the above- described recombinant DNA molecules encodes a peptide, protein, antisense RNA, sense RNA and/or ribozyme.
  • the recombinant DNA molecule or vector of the invention can be used alone or as part of a vector to express heterologous DNA sequences, which, e.g., encode proteins other than Flk-1 , in cells of the blood vessel wall, i.e., endothelial cells, for, e.g., gene therapy or diagnostics of vascular diseases such as atherosclerosis.
  • the recombinant DNA molecule or vector containing DNA sequence encoding a protein of interest is introduced into endothelial cells which in turn produce the protein of interest.
  • sequences encoding t-PA (Pennica, Nature 301 (1982), 214), p21 cell cycle inhibitor (El-Deiry, Cell 75 (1993), 817-823), or nitric oxide synthase (Bredt, Nature 347 (1990), 768-770) may be operatively linked to the endothelial cell-specific regulatory sequences of the invention and expressed in endothelial cells.
  • thrombolytic agents can be expressed under the control of the endothelial cell-specific regulatory sequences of the invention for expression by vascular endothelial cells in blood vessels, e.g., vessels occluded by aberrant blood clots.
  • heterologous proteins e.g., proteins which inhibit smooth muscle cell proliferation, e.g., interferon- ⁇ and atrial natriuretic polypeptide
  • proteins which inhibit smooth muscle cell proliferation e.g., interferon- ⁇ and atrial natriuretic polypeptide
  • the endothelial cell-specific regulatory sequences of the invention may also be used in gene therapy to promote angiogenesis to treat diseases such as peripheral vascular disease or coronary artery disease (Isner, Circulation 91 (1995), 2687- 2692).
  • the regulatory sequences of the invention can be operatively linked to sequences encoding cellular growth factors which promote angiogenesis, e.g., VEGF, acidic fibroblast growth factor, basic fibroblast growth factor and the like.
  • said protein is selected from the group consisting of Vascular Endothelial Growth Factor (VEGF), Hypoxia Inducible Factors (HIF), HIF-Related Factor (HRF), tissue plasminogen activator, p21 cell cycle inhibitor, nitric oxide synthase, interferon- ⁇ , atrial natriuretic polypeptide and monocyte chemotactic proteins.
  • VEGF Vascular Endothelial Growth Factor
  • HIF Hypoxia Inducible Factors
  • HRF HIF-Related Factor
  • tissue plasminogen activator p21 cell cycle inhibitor
  • nitric oxide synthase interferon- ⁇
  • atrial natriuretic polypeptide and monocyte chemotactic proteins.
  • said protein is a scorable marker, preferably luciferase, green fluorescent protein or lacZ.
  • a scorable marker preferably luciferase, green fluorescent protein or lacZ.
  • endothelial cells can be cultured with VEGF in the presence and absence of the candidate compound in order to determine whether the compound affects the expression of genes which are under the control of regulatory sequences of the invention, which can be measured, e.g., by monitoring the expression of the above-mentioned marker.
  • other marker genes may be employed as well, encoding, for example, selectable marker which provide for the direct selection of compounds which induce or inhibit the expression of said marker.
  • the regulatory sequences of the invention may also be used in methods of antisense therapy.
  • Antisense therapy may be carried out by administering to an animal or a human patient, a recombinant DNA containing the endothelial cell- specific regulatory sequences of the invention operably linked to a DNA sequence, i.e., an antisense template which is transcribed into an antisense RNA.
  • the antisense RNA may be a short (generally at least 10, preferably at least 14 nucleotides, and up to 100 or more nucleotides) nucleotide sequence formulated to be complementary to a portion of a specific mRNA sequence. Standard methods relating to antisense technology have been described (Melani, Cancer Res.
  • the antisense RNA binds to its target mRNA molecules within a cell, thereby inhibiting translation of the mRNA and down-regulating expression of the protein encoded by the mRNA.
  • an antisense sequence complementary to a portion of or all of the Flk-1 (KDR) mRNA would inhibit the expression of Flk-1 , which in turn would inhibit angiogenesis.
  • Such antisense therapy may be used to treat cancer, particularly to inhibit angiogenesis at the site of a solid tumor, as well as other pathogenic conditions which are caused by or exacerbated by angiogenesis, e.g., inflammatory diseases such as rheumatoid arthritis, and diabetic retinopathy.
  • the expression of other endothelial cell proteins may also be inhibited in a similar manner, for example, endothelial cell proteins such as cell cycle proteins (thereby inhibiting endothelial cell proliferation, and therefore, angiogenesis); coagulation factors such as von Willebrand factor; and endothelial cell adhesion factors, such as ICAM-1 and VCAM-1 (Bennett, J. Immunol. 152 (1994), 3530-3540).
  • said antisense RNA or said ribozyme are directed against a gene involved in vasculogenesis and/or angiogenesis and/or tumors of endothelial origin.
  • the invention relates to nucleic acid molecules of at least 15 nucleotides in length hybridizing specifically with a regulatory sequence as described above or with a complementary strand thereof. This means that they hybridize, preferably under stringent conditions, specifically with the nucleotide sequences as described above and show no or very little cross-hybridization with nucleotide sequences having no or substantially different regulatory properties.
  • nucleic acid molecules may be used as probes and/or for the control of gene expression. Nucleic acid probe technology is well known to those skilled in the art who will readily appreciate that such probes may vary in length. Preferred are nucleic acid probes of 17, 18, 19, 20 to 25 and 25 to 35 nucleotides in length.
  • nucleic acids of up to 100 and more nucleotides in length may also be appropriate to use.
  • the nucleic acid probes of the invention are useful for various applications. On the one hand, they may be used as PCR primers for amplification of regulatory sequences according to the invention. Another application is the use as a hybridization probe to identify regulatory sequences hybridizing to the regulatory sequences of the invention by homology screening of genomic DNA libraries.
  • Nucleic acid molecules according to this preferred embodiment of the invention which are complementary to a regulatory sequence as described above may also be used for repression of expression of a gene comprising such regulatory sequences, for example due to an antisense or triple helix effect or for the construction of appropriate ribozymes (see, e.g., EP-B1 0 291 533, EP-A1 0 321 201 , EP-A2 0 360 257) which specifically cleave the (pre)-mRNA of a gene comprising a regulatory sequence of the invention. Selection of appropriate target sites and corresponding ribozymes can be done as described for example in Steinecke, Ribozymes, Methods in Cell Biology 50, Galbraith et al.
  • nucleic acid probe with an appropriate marker for specific applications, such as for the detection of the presence of a nucleic acid molecule of the invention in a sample derived from an organism.
  • Such molecules may either be DNA or RNA or a hybrid thereof.
  • said nucleic acid molecule may contain, for example, thioester bonds and/or nucleotides analogues, commonly used in oligonucleotide anti-sense approaches. Said modifications may be useful for the stabilization of the nucleic acid molecule against endo- and/or exonucleases in the cell.
  • Said nucleic acid molecules may also be transcribed by an appropriate vector containing a chimeric gene which allows for the transcription of said nucleic acid molecule in the cell.
  • Such nucleic acid molecules may further contain ribozyme sequences which specifically cleave the (pre)-mRNA comprising the regulatory sequence of the invention.
  • oligonucleotides can be designed which are complementary to a regulatory sequence of the invention (triple helix; see Lee, Nucl. Acids Res. 6 (1979), 3073; Cooney, Science 241 (1988), 456 and Dervan, Science 251 (1991 ), 1360), thereby preventing transcription and the production of the encoded protein.
  • the present invention also relates to vectors, particularly plasmids, cosmids, viruses, bacteriophages used conventionally in genetic engineering that comprise a recombinant DNA molecule of the invention.
  • said vector is an expression vector and/or a targeting vector.
  • Expression vectors derived from viruses such as retroviruses, vaccinia virus, adeno-associated virus, herpes viruses, or bovine papilloma virus may be used for delivery of the recombinant DNA molecule or vector of the invention into targeted cell population.
  • viruses such as retroviruses, vaccinia virus, adeno-associated virus, herpes viruses, or bovine papilloma virus.
  • Methods which are well known to those skilled in the art can be used to construct recombinant viral vectors; see, for example, the techniques described in Sambrook, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory (1989) N.Y. and Ausubel, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. (1989).
  • the recombinant DNA molecules and vectors of the invention can be reconstituted into liposomes for delivery to target cells.
  • the Flk-1 promoter was stimulated by HIF-2 ⁇ , a basic helix-loop-helix/PAS domain transcription factor related to hypoxia-inducible factor-1.
  • HIF-2 ⁇ has previously been shown to stimulate the expression of VEGF, suggesting that HIF-2 ⁇ may regulate the coordinate expression of both the VEGF receptor Flk-1 and its ligand in vivo.
  • Flk-1 gene regulatory elements described herein can be used together with HIF-2 ⁇ for the elucidation of the molecular mechanisms involved in endothelial cell specification and angiogenesis, and can be used to target expression of any transgene to the endothelium.
  • the vector of the invention furthers comprises a gene capable of expressing HIF-2 ⁇ .
  • the present invention furthermore relates to host cells transformed with a DNA molecule or vector of the invention.
  • Said host cell may be a prokaryotic or eukaryotic cell.
  • the vector or recombinant DNA molecule of the invention which is present in the host cell may either be integrated into the genome of the host cell or it may be maintained extrachromosomally.
  • the recombinant DNA molecule of the invention can be used for "gene targeting" and/or “gene replacement", for restoring a mutant gene or for creating a mutant gene via homologous recombination.
  • the host cell can be any prokaryotic or eukaryotic cell, such as a bacterial, insect, fungal, plant or animal cell.
  • Preferred fungal cells are, for example, those of the genus Saccharomyces, in particular those of the species S. cerevisiae.
  • Suitable mammalian cell lines comprise Saos-2 human osteosarcoma cells (ATCC HTB-85), HeLa human epidermoid carcinoma cells (ATCC CRL-7923), HepG2 human hepatoma cells (ATCC HB-8065), human fibroblasts (ATCC CRL-1634), U937 human histiocytic lymphoma cells (ATCC CRL-7939), RD human embryonal rhabdomyosarcoma cells (ATCC CCL-136), MCF7 human breast adenocarcinoma cells (ATCC HTB-22), JEG-3 human choriocarcinoma cells (ATCC HB36), A7r5 fetal rat aortic smooth muscle cells (ATCC CRL-1444), and NIH 3T3 mouse fibroblasts (ATCC CRL-1658) obtainable from the American Type Culture Collection.
  • Primary- culture HUVEC may be obtained from Clonetics Corp. (San Diego, CA) and can be grown in EGM medium containing 2% fetal calf serum (Clonetics).
  • Primary-culture human aortic and intestinal smooth muscle cells can also be obtained from Clonetics Corp.
  • Most preferably said host cell is an endothelial cell or derived therefrom, such as BAE cells.
  • a further embodiment of the invention concerns the above-described cells which further comprise a recombinant DNA molecule or vector containing a gene capable of expressing HIF-2 ⁇ .
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising at least one of the aforementioned recombinant DNA molecules or vectors of the invention, either alone or in combination, and optionally a pharmaceutically acceptable carrier or excipient.
  • suitable pharmaceutical carriers include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc.
  • Compositions comprising such carriers can be formulated by well known conventional methods.
  • These pharmaceutical compositions can be administered to the subject at a suitable dose. Administration of the suitable compositions may be effected by different ways, e.g. by intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration.
  • the dosage regimen will be determined by the attending physician and other clinical factors. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. Dosages will vary but a preferred dosage for intravenous administration of DNA is from approximately 10 6 to 10 22 copies of the DNA molecule.
  • the compositions of the invention may be administered locally or systemically. Administration will generally be parenterally, e.g., intravenously; DNA may also be administered directly to the target site, e.g., by biolistic delivery to an internal or external target site or by catheter to a site in an artery.
  • the various recombinant DNA molecules and vectors of the invention are administered either alone or in any combination using standard vectors and/or gene delivery systems, and optionally together with an appropriate compound, for example VEGF, and/or together with a pharmaceutically acceptable carrier or excipient.
  • said recombinant DNA molecules may be stably integrated into the genome of the mammal.
  • viral vectors may be used which are specific for certain cells or tissues, preferably for the endothelium and persist in said cells. Suitable pharmaceutical carriers and excipients are well known in the art.
  • the pharmaceutical compositions prepared according to the invention can be used for the prevention or treatment or delaying of different kinds of diseases, which are related to the expression or overexpression of a given gene or genes in the endothelium.
  • a pharmaceutical composition of the invention which comprises a recombinant DNA molecule or vector of the invention in gene therapy.
  • Suitable gene delivery systems may include liposomes, receptor-mediated delivery systems, naked DNA, and viral vectors such as herpes viruses, retroviruses, adenoviruses, and adeno-associated viruses, among others. Delivery of nucleic acids to a specific site in the body for gene therapy or antisense therapy may also be accomplished using a biolistic delivery system, such as that described by Williams (Proc. Natl. Acad. Sci. USA 88 (1991), 2726-2729).
  • Standard methods for transfecting cells with recombinant DNA are well known to those skilled in the art of molecular biology, see, e.g., WO 94/29469.
  • Gene therapy and antisense therapy to prevent or decrease the development of atherosclerosis or inhibit angiogenesis may be carried out by directly administering the recombinant DNA molecule or vector of the invention to a patient or by transfecting endothelial cells with the recombinant DNA molecule or vector of the invention ex vivo and infusing the transfected cells into the patient.
  • research pertaining to gene transfer into cells of the germ line is one of the fastest growing fields in reproductive biology.
  • Gene therapy which is based on introducing therapeutic genes into cells by ex-vivo or in-vivo techniques is one of the most important applications of gene transfer. Suitable vectors and methods for in-vitro or in-vivo gene therapy are described in the literature and are known to the person skilled in the art; see, e.g., W094/29469, WO 97/00957 or Schaper (Current Opinion in Biotechnology 7 (1996), 635-640) and references cited therein.
  • the DNA molecules and vectors comprised in the pharmaceutical composition of the invention may be designed for direct introduction or for introduction via liposomes, or viral vectors (e.g. adenoviral, retroviral) containing said recombinant DNA molecule into the cell.
  • said cell is a germ line cell, embryonic cell, or egg cell or derived therefrom.
  • the pharmaceutical compositions according to the invention can be used for the treatment of all kinds of diseases hitherto unknown as being related to the expression and/or over expression of genes in the endothelium.
  • the present invention also relates to diagnostic compositions or kits comprising at least one of the aforementioned recombinant DNA molecules, vectors, cells and/or nucleic acid molecules and, in the case of diagnostic compositions, optionally suitable means for detection.
  • kits of the invention may further contain compounds such as further plasmids, antibiotics and the like for screening transgenic animals and/or animal cells useful for the genetic engineering of non- human animals, preferably mammals and most preferably mouse.
  • the introduced recombinant DNA molecules and vectors of the invention express the heterologous DNA sequence after introduction into said cell and preferably remain in this status during the lifetime of said cell.
  • cell lines which stably express the heterologous DNA under the control of the regulatory sequence of the invention may be engineered.
  • host cells can be transformed with the recombinant DNA molecule or vector of the invention and a selectable marker, either on the same or separate vectors.
  • engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media.
  • the selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines.
  • This method may advantageously be used to engineer cell lines which express the heterologous DNA sequence under the control of the regulatory sequence of the invention, and which respond to VEGF and/or hypoxia mediated signal transduction. Such engineered cell lines are particularly useful in screening compounds capable of modulating Flk-1 gene expression.
  • a number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, Cell 11 (1977), 223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska, Proc. Natl. Acad. Sci. USA 48 (1962), 2026), and adenine phosphoribosyltransferase (Lowy, Cell 22 (1980), 817) genes can be employed in tk “ , hgprt " or aprt " cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate (Wigler, Proc.
  • trpB which allows cells to utilize indole in place of tryptophan
  • hisD which allows cells to utilize histinol in place of histidine
  • ODC ornithine decarboxyiase
  • DFMO 2-(difluoromethyl)-DL-ornithine
  • the person skilled in the art may also use the regulatory sequences of the invention to "knock out" an endogenous gene comprising identical or similar regulatory sequences, for example, by gene targeting, cosuppression, triple helix, antisense or ribozyme technology.
  • the present invention also relates to a method for the production of a transgenic animal, preferably mouse, comprising introduction of a recombinant DNA molecule or vector of the invention into a germ cell, an embryonic cell or an egg or a cell derived therefrom.
  • the non-human animal to be used in the method of the invention may be a wildtype, i.e. healthy animal, or may have a disease or disorder, preferably a disease or disorder which is dependent on neovascularization, such as solid tumors, retinopathy, arthritis, psoriasis.
  • Said disease or disorder may be an inborn insufficiency or natural developed or caused by genetical engineering, for instance by the expression of a DNA sequence encoding a protein involved in neuronal development and/or diseases as described above, preferably under the control of the regulatory sequence of the invention.
  • the invention also relates to transgenic non-human animals comprising a recombinant DNA molecule or vector of the invention or obtained by the method described above, preferably wherein said recombinant DNA molecule is stably integrated into the genome of said non-human animal, preferably such that the presence of said recombinant DNA molecule or vector leads to the transcription and/or expression of the heterologous DNA sequence by the regulatory sequence of the invention.
  • transgenic non-human animals comprising a recombinant DNA molecule or vector of the invention or obtained by the method described above, preferably wherein said recombinant DNA molecule is stably integrated into the genome of said non-human animal, preferably such that the presence of said recombinant DNA molecule or vector leads to the transcription and/or expression of the heterologous DNA sequence by the regulatory sequence of the invention.
  • Further non-human animals which may be employed according to the embodiments of the invention as described above are well known to the person skilled in the art and comprise rat, hamster, dog, monkey, rabbit
  • the present invention relates to a method for the identification of a chemical and/or biological substance capable of suppressing or activating and/or enhancing the transcription of a gene in endothelial cells comprising:
  • Said plurality of compounds may be comprised in, for example, samples, e.g. cell extracts from, e.g. plants, animals or microorganisms. Furthermore, said compounds may be known in the art but hitherto not known to be capable of suppressing or activating and/or enhancing the transcription of a gene in endothelial cells. The plurality of compounds may be, e.g., added to the culture medium or injected into the animals.
  • plural of compounds in a method of the invention is to be understood as a plurality of substances which are either identical or not. If a sample containing a plurality of compounds is identified in the method of the invention, then it is either possible to isolate the compound from the original sample identified as containing the compound capable of suppressing or activating and/or enhancing the transcription of a gene in endothelial cells, or one can further subdivide the original sample, for example, if it consists of a plurality of different compounds, so as to reduce the number of different substances per sample and repeat the method with the subdivisions of the original sample.
  • the sample identified according to the method of the invention only comprises a limited number of or only one substance(s).
  • said sample comprises substances of similar chemical and/or physical properties, most preferably said substances are identical.
  • Determining whether a compound is capable of suppressing or activating and/or enhancing the transcription of a gene in endothelial cells can be done, for example, in mice by monitoring reporter gene expression or by monitoring behavior of the transgenic non-human animals of the invention contacted with the compounds compared to that of wild-type animals or compared to a transgenic non-human animal contacted with a compound which is either known to be capable or incapable of suppressing or activating and/or enhancing the transcription of a gene in endothelial cells of said transgenic non-human animal of the invention.
  • the person skilled in the art can monitor the physical behavior, or for example the movement of the above-described animals. Such methods are well known in the art.
  • Such regulators of Flk-1 gene expression may be used in processes such as wound healing; in contrast, antagonists of expression may be used in the treatment of tumors that rely on vascularization for growth.
  • the present invention provides methods for identifying compounds which modulate VEGF receptor (e.g., Flk-1 or Flt1) gene expression.
  • Compounds found to downregulate expression of a VEGF receptor gene can be used in methods to inhibit angiogenesis, while compounds found to enhance Flk-1 or Flt1 expression can be used in methods to promote angiogenesis, for example, to promote wound healing (e.g., healing of broken bones, burns, diabetic ulcers, and traumatic or surgical wounds) or to treat peripheral vascular disease, atherosclerosis, cerebral vascular disease, hypoxic tissue damage (e.g., retinopathy, hypoxic damage to heart tissue), diabetic pathologies such as chronic skin lesions, or coronary vascular disease.
  • wound healing e.g., healing of broken bones, burns, diabetic ulcers, and traumatic or surgical wounds
  • peripheral vascular disease e.g., atherosclerosis, cerebral vascular disease, hypoxic tissue damage (e.g., retinopathy, hypoxic damage to heart tissue), diabetic pathologies such as chronic skin lesions, or coronary vascular disease.
  • hypoxic tissue damage e.g
  • These compounds can also be used to treat patients who have, or have had, transient ischemic attacks, vascular graft surgery, balloon angioplasty, frostbite, gangrene, or poor circulation.
  • Compounds identified as having the desired effect i.e., enhancing or inhibiting Flk-1 expression
  • the present invention also relates to a method for the production of a pharmaceutical composition comprising the steps of the method of the invention and formulating the compound identified in step (b) in a pharmaceutically acceptable form.
  • the therapeutic compounds identified using the method of the invention may be administered to a patient by any appropriate method for the particular compound, e.g., orally, intravenously, parenterally, transdermally, transmucosally, or by surgery or implantation (e.g., with the compound being in the form of a solid or semi-solid biologically compatible and resorbable matrix) at or near the site where the effect of the compound is desired.
  • a salve or transdermal patch that can be directly applied to the skin so that a sufficient quantity of the compound is absorbed to increase vascularization locally may be used. This method would apply most generally to wounds on the skin. Salves containing the compound can be applied topically to induce new blood vessel formation locally, thereby improving oxygenation of the area and hastening wound healing. Therapeutic doses are determined to be appropriate by one skilled in the art.
  • identification of transacting factors which interact with the regulatory sequences of the invention can form the basis for the development of novel therapeutics for modulating conditions associated with endothelial cell growth, such as angiogenesis, vascular disease, and wound healing.
  • Identification of transacting factors is carried out using standard methods in the art (see, e.g., Sambrook, supra, and Ausubel, supra).
  • standard DNA footprinting and/or native gel-shift analyses can be carried out.
  • the regulatory sequences can be used as an affinity reagent in standard protein purification methods, or as a probe for screening an expression library.
  • transacting factor modulation of its binding to the regulatory sequence in the Flk-1 gene can be pursued, beginning with, for example, screening for inhibitors of transacting factor binding.
  • Enhancement of Flk-1 expression in a patient, and thus enhancement of angiogenesis may be achieved by administration of the transacting factor, or the gene encoding it (e.g., in a vector for gene therapy).
  • the active form of the transacting factor is a dimer, dominant-negative mutants of the transacting factor could be made in order to inhibit its activity.
  • further components in the pathway of Flk-1 signal transduction can be identified. Modulation of the activities of these components can then be pursued, in order to develop additional drugs and methods for modulating endothelial cell growth and angiogenesis.
  • VEGF and its receptor play an important role in the onset of angiogenic disease.
  • Transgenic non-human animals expressing VEGF and/or its receptor gene and/or mutated versions thereof under the control of the regulatory sequences of the invention can now be used for the identification of substances, which, for example, are capable of restoring the wild-type interaction of mutated VEGF and its receptor either or both of which bear mutations.
  • Some genetic changes lead to altered protein conformational states. Genetic changes may therefore result in a decreased binding activity of VEGF. Restoring the activity of mutant VEGF protein or increasing the activity of other proteins which interact with mutant VEGF proteins is the most elegant and specific means to correct these molecular defects.
  • the methods of the invention are also useful to screen e.g., antibody, Fab, Fv or scFv expression libraries wherein the DNA sequence encoding said antibodies or derivatives thereof are under the control of the regulatory sequence of the invention. It is, of course, evident to the person skilled in the art that also other protein or peptide expression libraries using the regulatory sequences of the invention may be employed.
  • the present invention relates to the use of the recombinant DNA molecule, vector, cell, pharmaceutical compositions, diagnostic compositions or a transgenic non-human animal of the invention for the identification of a chemical and/or biological substance capable of suppressing or activating and/or enhancing the transcription, expression and/or activity of genes and/or its expression products in endothelial cells.
  • the chemical or biological substance used in the methods and uses of the present invention is selected from the group consisting of peptides, proteins, nucleic acids, antibodies, small organic compounds, hormones, neural transmitters, peptidomimics, and PNAs (Milner, Nature Medicine 1 (1995), 879-880; Hupp, Cell 83 (1995), 237-245; Gibbs, Cell 79 (1994), 193-198).
  • the present invention further relates to a method of inhibiting a vascular disease in a subject, comprising contacting an artery of said subject with the recombinant DNA molecule or vector of the invention, wherein said protein reduces or prevents the development of the vascular disease, preferably said protein reduces proliferation of smooth muscle cells.
  • the present invention relates to the use of a recombinant DNA molecule, vector, nucleic acid molecule of the invention and/or substance identified by a method of the invention for the preparation of a composition for directing and/or preventing expression of genes specifically in endothelial cells and/or for the preparation of a pharmaceutical composition for treating, preventing and/or delaying a vascular disease and/or a tumorous disease in a subject.
  • the upregulation and activation of the Flk-1 receptor in peri-tumoral endothelial cells is believed to be involved in the neovascularization of various human or experimental tumors (Plate, 1994; Ferrara, Curr. Opin. Nephrol. Hypertens. 5 (1996), 35-44).
  • the present invention relates to the use of a recombinant DNA molecule, vector and/or the nucleic acid molecule of the invention for the preparation of a pharmaceutical composition for inducing a vascular disease in a non-human animal or in a transgenic non-human animal described above.
  • the vascular disease is atherosclerosis and/or a neuronal disorder.
  • a neuronal disorder is atherosclerosis and/or a neuronal disorder.
  • the recombinant DNA molecules, vectors, nucleic acid molecules, compounds, uses and methods of the invention can be used for the treatment of all kinds of disorders and diseases hitherto unknown as being related to or dependent on the modulation of genes specifically expressed in the endothelium.
  • the recombinant DNA molecules, vectors, nucleic acid molecules, compounds, methods and uses of the present invention may be desirably employed in humans, although animal treatment is also encompassed by the methods and uses described herein.
  • the present invention provides for the use of a regulatory sequence as defined above for enhancing and/or directing gene expression in endothelial cells in any kind of organism.
  • Figure 1 Nucleotide sequence of the murine Flk-1 gene. The ATG codon is at position +299. The three exons are indicated in bold. Motifs for transcription factors are underlined. VRE: vascular response element,
  • Figure 2 Map of reporter gene construct pGL2-B. Arrows symbolize functional elements. Luc: luciferase gene, AMP: ampicillin resistance gene, flori: replication origin for bacteriophage f1.
  • Figure 3 Map of reporter gene construct pGLacZ. Arrows symbolize functional elements. LacZ: ⁇ -galactosidase gene, AMP: ampicillin resistance gene, flori: replication origin or bacteriophage f1.
  • Figure 4 Partial structure and functional analysis of the mouse Flk-1 locus.
  • Figure 5 Analysis of the intron in transgenic mice. The embryo (10.5 days) was stained overnight with X-Gal. The reporter gene was under the control of the intron enhancer (3'-ln1 , cf. Fig. 4A) and of the Flk-1 promoter fragment ranging from nucleotides -4100 to +299. A) Top lateral view. B) Top dorso-cranial view.
  • Figure 6 Histological evaluation of a transgenic embryo. The embryo shown in Fig. 5 was embedded in paraffin. The cuts were stained with neutral red. A) Pseudo transversal cut through the head region. B) Magnification of a section from A. C) Pseudo transversal cut of a caudal region. 1 : 4th ventricle of cerebrum, 2: acoustic vesicle/otocyte, 3: V. cardinalis anterior. 4: third ventricle of cerebrum. 5: endbrain vesicle. 6: optic vesicle. 7: ganglion trigeminale (V). 8: chorda dorsalis.
  • Figure 7 Functional analysis of the first two introns of the Flk-1 gene in vivo.
  • the depicted embryo (10.5 days) carries the ⁇ -galactosidase gene under the control of the Flk-1 promoter (-4.1 kbp to +299 bp) and the first 6.2 kbp of the transcribed region (cf. Fig. 4A).
  • the staining was carried out as described in Fig. 5.
  • Figure 8 In vivo characterization of the intron enhancer in combination with the strongest promoter fragment. All three embryos carry the ⁇ - galactosidase gene under the control of the Flk-1 promoter fragment of bp -640 to bp +299 and the intron enhancer. The staining was carried out as described in Fig. 5.
  • Figure 9 Detailed analysis of the left-hand embryo from Fig. 8A) Left lateral view. B) Sectional magnification of A. C) Right lateral view.
  • Figure 10 Histological evaluation of the embryo depicted in Fig. 9. The embryo was embedded in paraffin and was cut into 10 ⁇ m slices. The cuts were stained with neutral red.
  • cardinalis anterior 7: neural tube
  • 8 esophagus
  • 9 V. cardinalis posterior
  • 10 aorta dorsalis
  • 11 endocardium of the heart atrium
  • 12 vessels of the myocardium.
  • FIG 11 Reporter gene analysis of Flk-1 gene regulatory elements in transgenic mouse embryos.
  • the lacZ reporter gene was fused to regulatory elements derived from the mouse Flk-1 gene and tested for ⁇ -galactosidase expression in transgenic mouse embryos.
  • A) 10.5 day transgenic mouse embryo expressing lacZ under the control of a 939 bp promoter fragment in combination with a 2.3 kbp Xhol/BamHI fragment of the first intron spanning the region from +1677 bp to +3947 bp of the Flk-1 gene. This embryo was derived from a foster mother.
  • D-F Paraffin sections of the ⁇ -galactosidase stained embryo from (B) demonstrate ⁇ -galactosidase expression in the paired dorsal aortae (D), a venous vessel connected with the heart (E), and capillaries invading the neural tube (F).
  • D dorsal aortae
  • E a venous vessel connected with the heart
  • F capillaries invading the neural tube
  • G ⁇ -galactosidase expression in a transgenic embryo containing the tk promoter in combination with the 2.3 kbp Xhol/BamHI fragment of the Flk-1 first intron.
  • Figure 12 Nucleotide sequence of the Flk-1 intron enhancer and putative transcription factor binding sites. Sequences matching known transcription factor binding sites are underlined. This sequence is deposit in the GeneBank database (accession number AF061804).
  • FIG. 13 Analysis of transgene expression during early development and in newborn mice.
  • the transgenic mouse line 2603 expresses lacZ under the control of the Flk-1 promoter (-640 bp/+299 bp) in combination with the 2.3 kbp Flk-1 intronenhancer
  • B) and C) Paraffin sections from the embryo shown in A demonstrate transgene expression in endothelial cells of the allantois (B) and the yolk sac (C).
  • D-H LacZ staining of spleen (D), kidney (E), lung (F), liver (G) and thymus (H) from a postnatal day 5 transgenic mouse.
  • EM extraembryonic mesoderm. Bars, 25 ⁇ M (C), 100 ⁇ M (B,D,E,F,G,H).
  • FIG 14 The 5 ' -UTR is required for expression of the Flk-1 gene in the yolk sac vasculature.
  • Transgenic mouse embryos that contain a Flk-1 promoter and 5 ' UTR (-640 bp ⁇ +299 bp) / enhancer (+1677 bp/+3947 bp) reporter gene construct show a complete vascular expression in the yolk sac vasculature (A and B).
  • the yolk sac of Flk- 1/lacZ knock-in embryos which lack part of the 5 ' UTR show expression only in large collecting vessels that connect with the embryo, but not in the smaller vessels (C). Bar, 500 ⁇ M.
  • FIG. 15 HIF-2 ⁇ stimulates Flk-1 gene expression.
  • A293 cells were co- transfected with a reporter gene construct containing Flk-1 promoter sequences from bp -640 to bp +299 and with expression vectors encoding the murine HIF-1 ⁇ and HIF-2 ⁇ cDNAs, respectively.
  • Relative promoter activities were determined as described in Materials and Methods. The promoter activity of the control transfection was arbitrarily set to 1.
  • DNA clones containing the 5' region of the mouse Flk-1 gene were isolated from a library prepared from 129/SvJ mice in ⁇ Dash II vector (Stratagene) (Ronicke, supra) or in ⁇ FIX II or obtained from the P1 Library (Genome Systems, St. Louis).
  • a 21 kb region of the mouse Flk-1 gene, contained in the DNA insertions of two ⁇ phages 6 and 16, including approximately 15 kb of 5' flanking sequences, exons 1 , 2 and 3, and introns 1 and 2 was characterized by restriction enzyme mapping and Southern blot analysis. Lower DNA fragments of the phage clones were cloned into pBluescript vector DNA (Stratagene) and used for further characterization.
  • Sequencing was performed using an automatic Sequencer (373A, Applied Biosystems).
  • the nucleotide sequence of the Flk-1 intron enhancer is deposited in the Genbank database (accession number AF061804).
  • the search for potential transcription factor binding sites was performed with the Matlnspector software (Quandt, (1995) Nucl. Acids Res. 23, 4878-4884).
  • FIG. 1 The DNA sequence (SEQ ID NO: 1 ) of a 12.8 kb region spanning from about position -6,660 kb (relative to the transcriptional start site) to approximately position +6,135 kb (located in the third exon) was determined (Fig. 1 ).
  • Figure 4A shows a schematic representation of the first 6.5 kbp of the transcribed region of the murine Flk-1 gene. Exons I, II and III are emphasized as hatched boxes. The first intron having a length of 3.6 kbp is subdivided into two regions (5'-ln1 and 3'-ln1 ).
  • the region ln-2 contains the entire second intron, the second exon, the 3' end of the first intron and part of the third exon. This subdivision into various intron fragments was maintained in the following analyses.
  • the reporter gene constructs used were derived from pGL2 basic vector (Promega) that contains a promoterless luciferase gene. Luciferase reporter gene constructs were generated for transfection of cells in vitro. For use in transgenic mice in vivo, plasmids were used in which the luciferase reporter gene was replaced by a lacZ reporter gene.
  • Flk-1 promoter fragments were amplified by PCR and cloned into pGL2 (Promega) vector DNA 5' to the luciferase gene as described by Ronicke, supra; see also Figure 2.
  • the upstream primers used were -1900: 5'-GGG GTA CCG AAT TCT AAA TGG GGC GAT TAC C-3' (SEQ ID NO 2); -640: 5'-GTG GTA CCC AAA CAC TCA ACA CCA CTG-3'(SEQ ID NO: 3); -624, 5'-TCG GTA CCG ACC CAG CCA GGA AGT TC-3' (SEQ ID NO: 4); the downstream primer was +299, 5'-TTG CTA AGC TTC CTG CAC CTC GCG CTG GG-3' (SEQ ID NO: 5).
  • a Hindlll-EcoRI fragment of recombinant lambda phage 6 from P1 Library was inserted into the plasmid ranging from -1900 to +299.
  • Vectors that contained Flk-1 intron sequences in addition to promoter sequences were generated as follows: specific intron sequences were amplified by PCR from cloned Flk-1 genomic DNA and inserted downstream of the reporter gene.
  • Primers used for amplification were 5'-ln1down: 5'-AGG GAT CCA CTC TTT AGT AGT AAG GCG-3' (nucleotides 7036-7057 of SEQ ID NO: 1 , SEQ ID NO: 6); 5'- Inlup: 5'-ACC TCG AGA CTT GGA TGG CAC-3' (nucleotides 8324-8342 of SEQ ID NO: 1 , SEQ ID NO: 7); 3'-ln1down: 5'-GGG CTA TAA TTG GTG CCA TCC-3' (nucleotides 8312-8332 of SEQ ID NO: 1 , SEQ ID NO: 8); 3'-ln1up: 5'-GGA TGG AGA AAA TCG CCA GGC-3' (nucleotides 10637-10658 of SEQ ID NO: 1 , SEQ ID NO: 9); IN2A: 5'-GTG TGC ATT GTT TAT GGA AGG G
  • Fig. 3 represents a modification of the pGL2 basic vector in which the corresponding Flk-1 promoter fragments were inserted into the Kpnl and Hindlll restriction sites of the polylinker (Fig. 2). Also the luciferase reporter gene was replaced by the ⁇ -galactosidase gene (Schlaeger, Proc. Natl. Acad. Sci. USA 94 (1997), 3058-3063). For an analysis of the intron intron fragments were cloned into the BamHI and Sail restriction sites indicated. DNA manipulations, PCR amplification and DNA sequencing were performed according to conventional methods known in the art as described, for example in Sambrook, supra and PCR Technology, Griffin and Griffin, eds., RC Press London (1994).
  • Figure 4 shows the result of transient transfections in BAECs.
  • the corresponding intron fragments were combined with a Flk-1 promoter fragments which comprised nucleotides -640 to +299.
  • the promoter activity was standardized with respect to the promoter activity of the construct containing the 5'-ln1 fragment.
  • Tissue culture and transient transfections were performed as follows: All cells were cultured in DMEM+ supplemented with 10% FCS (Sigma) and as described in Schaeger, 1997.
  • bEnd ⁇ cells were generated by transformation with the Polyoma middle-T oncogene as described earlier (Montesano, Cell 62 (1990), 435- 445).
  • Bovine aortic endothelial cells were prepared as described (Schwartz, In Vitro 14 (1978), 966-980).
  • NIH 3T3, C2C12 and L cells were obtained from ATCC.
  • Transient transfections were performed using the CaP0 4 -precipitation method according to Chen and Okayama (Mol. Cell Biol. 7 (1987), 2745-2752), optionally with modifications as described (Ronicke, 1996). The transfection efficiency was monitored by co-transfection of a ⁇ -galactosidase reporter vector. Each construct was transfected at least six times in three independent experiments. Cells were grown to 70% confluence in 6-cm dishes prior to transfection.
  • Chlorophenol red- ⁇ -D-galactopyranoside (CPRG) was used as a substrate and the conversion was measured at 575 nm in an ELISA-reader (Biometra). Extracts were diluted to obtain OD 575 nm values between 0.2 and 0.8. These values were used to standardize for transfection efficiency after subtracting a background value, as determined from a cell extract of a transfection without lacZ-reporter plasmid but with a luciferase- reporter plasmid. Luciferase-reporter gene assays were performed with the same extracts as described by the manufacturer (Promega). Luciferase activity was measured with a luminometer (LB96P, Berthold) and calculated as per cent of the activity of the pGL2-promoter plasmid (Promega).
  • Table I Functional analysis of the intron of the Flk-1 gene.
  • the upper line indicates the corresponding intron fragment which was analyzed in combination with the Flk-1 promoter (-640 bp/+299 bp).
  • Figure 4C shows the results of another transfection assay of the intron fragments. It was carried out as described above, with the exception that a Flk-1 promoter fragments was used that comprised the region between nucleotides -4100 and +299. Also, a fragment was analyzed that contained the entire first intron, the second exon, the second intron and part of the third exon shown in Figure 4A.
  • Table II Functional analysis of introns of the Flk-1 gene.
  • the upper line indicates the corresponding intron fragment which was analyzed in combination with the Flk-1 promoter (-4100 Bp/+299 Bp).
  • This regulatory sequence is located in the region between the Xhol and BamHI restriction site in the first intron of the Flk-1 gene (cf. Fig. 4A). It is functional in both orientations since the intron is used in an antiparallel manner with respect to the Flk- 1 promoter fragment in the construct referred to as 3'-ln 1. In construct ln1+2, however, the original orientation was maintained.
  • a sequence analysis of the intron enhancer lead to the identification of two potential GATA binding sites at position +1927 bp and +3514 bp; (Evans, Proc. Natl.
  • Example 3 Functional characterization of the Flk-1 promoter in vivo.
  • the constructs were based on plasmid pGL- 2B described in Figure 2 with the exception that the luciferase reporter gene was replaced by the ⁇ -galactosidase gene. All injection fragments used in the examples were obtained by restriction digestion with the enzymes Kpnl and Sail. Transgenic mice were generated as described by (Hogan, Manipulating the Mouse Embryo (1994), Cold Spring Harbor Laboratory Press, New York). Fertilized oocytes were isolated from superovulated C57BL/6 x C3H/He F1 mice, microinjected and reimplanted into pseudopregnant females of the same hybrid-mouse strain.
  • mice were sacrifized at day 10.5 or 11.5 of gestation, and embryos were analyzed by whole mount LacZ staining for transgene expression.
  • the embryos to be examined were isolated on day 10 after reimplantation of the injected oocytes. Analysis of the transgenic embryos revealed that although promoter activity could be detected, none of the constructs was capable of conferring reproducible expression of the reporter gene in the endothelium.
  • the intron which was identified in vitro was then examined for its function in vivo.
  • a construct similar to that shown in Figure 3 which contained an Flk-1 promoter fragment ranging from nucleotide -4100 to base pair +299 and the intron enhancer (3'-ln1 , cf. Fig. 4A).
  • the staining and fixation of the embryos was performed as follows: The mid-day of the plug observation was counted as E0.5.
  • the embryos were dissected out in ice-cold PBS and fixed in ice-cold 2 % (w/v) paraformaledehyd, 2 mM MgCI 2 , 2 mM EGTA, 0.1 M Pipes buffer, pH 6.9 for 15 to 120 minutes. The embryos were rinsed with PBS three times for 5 minutes each.
  • the LacZ expression was detected by incubating the embryos at 30 °C overnight in 0.1 % X-gal (5-bromo-4-chloro-3-indolyl- ⁇ -D-galactopyranoside), 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide 5 mM, 1 to 2 mM magnesium chloride, 0.002 to 0.02 % NP-40, 0.01 % or 0.25 mM sodium deoxycholate, PBS, pH 7.0. After the staining, embryos were rinsed in PBS and postfixed at 4 °C overnight in 2 % paraformaldehyde, 0.1 % glutaraldehyde, PBS, pH 7.0.
  • Figure 5 shows an embryo (embryonic day 10.5) which was isolated after injection of the fragment.
  • Figure 5A a color reaction in vessels of the developing brain can be clearly discerned. Also superficial vessels in the body's middle (dorsal) and a staining in the liver bud can be observed.
  • Figure 5B shows the dorsal, caudal region of the same embryo. It proves that the vessels in both halves of the head were stained.
  • FIG. 6 The results of the histological analysis are shown in Figure 6. It shows pseudo transversal cuts of the embryo.
  • section 6A a staining of the inner lining of the V. cardinalis anterior (3) and of other superficial vessels can be seen.
  • Figure 6B represents a strong magnification of a section of 6A with the staining of endothelial cells within the V. cardinalis anterior.
  • Figure 6C shows a more caudally located region.
  • the staining of the V. cardinalis anterior and of superficial vessels with wide lumen and thin walls as well as of vascular structures in the neural tube is clearly visible.
  • a staining of the chorda dorsalis (9) can be observed. However, in none of the cases a staining of arterial vessels could be observed.
  • Example 5 Functional analysis of the introns I and II of the murine Flk-1 gene in vivo
  • the intron enhancer in combination with an Flk-1 promoter fragment displayed an endothelium-specific function in transgenic mice covering a substantial part of the endogenous expression pattern
  • the further search for in vivo relevant, gene regulatory elements was extended to other intron regions.
  • the construct containing the promoter region between nucleotides -4100 to +299 and the first 6.5 kbp of the transcribed region (ln1+2; cf. Fig. 4) was used.
  • Figure 7 shows an embryo on embryonic day 10.5 which was obtained after injection of this fragment. Again, a staining of the vessels in the developing brain as well as superficial vessels the of the liver bud was visible. The following injections yielded four further transgenic embryos which displayed the same pattern.
  • FIG. 9A the left-hand embryo from Fig. 8 is shown in more detail.
  • the strong staining of the heart in the region of the atrium and ventricle is particularly clearly visible.
  • the vessels of the developing brain, the vessels between the somites, the aorta dorsalis as well as the fine capillary plexus on the body's surface are stained.
  • Figure 9B shows a sectional magnification of 9A.
  • Figure 9 The embryo shown in Figure 9 was embedded in paraffin and cut to slices. The cuts dyed with neutral red are shown in Fig. 10.
  • Figure 10A shows a pseudo transversal cut through the head region. Particularly prominent is the branching of the A. carotis interna (4) in addition to the staining of other vascular structures.
  • Figure 10B represents a magnification of a similar cut; here, too, the branching of the A. carotis interna is particularly striking.
  • Figure 10C shows a more caudal cut which in terms of its position roughly corresponds to the cut shown in Figure 6A.
  • an expression in the branching of the A. carotis interna (4) and other vascular structures is visible.
  • Figure 10D represents an even more caudally located region.
  • a staining in the venous endothelium (V. cardinalis posterior, 9) and in the arterial structures (aorta dorsalis, 10) can be observed.
  • the endocardium of the atrium as well as the vessels in the trabeculae of the heart ventricles display an expression.
  • a total of seven transgenic embryos was analyzed after injection of this fragment (- 640 bp/+299 bp/3'-ln1 ). Safe for one which showed no staining, all embryos displayed an expression of the ⁇ -galactosidase in endothelial structures.
  • Example 7 Endothelium-specific expression mediated by Flk-1 regulatory sequences in vivo
  • Sectioning of these embryos confirmed that the ⁇ -galactosidase protein was confined to vascular endothelium.
  • This in vivo analysis demonstrated that the intron sequences in combination with the Flk-1 promoter confer an endothelium-specific expression pattern that closely resembles the expression pattern of the endogenous Flk-1 gene (Millauer, 1993).
  • the intron fragment could also direct endothelial cell-specific lacZ expression when used in an inverted orientation in the reporter construct (Construct -640 bp/+299 bp/A+3947 bp/+1677 bp; see Table III).
  • Embryos transgenic for the constructs given above were generated, and LacZ staining and genotyping was performed at E10.5 or E11.5 as described in Example 4.
  • Constructs are defined by the position of the promoter or intron fragments in bp relative to the transcription initiation site of the endogenous Flk-1 gene.
  • TG number of transgenic embryos
  • ES number of embryos showing endothelial-specific staining
  • ET number of embryos showing ectopic staining
  • NO number of embryos showing no staining at all.
  • Transgenic mouse lines were generated with this reporter gene construct (-640 bp/+299 bp//+1677bp/+3947bp) containing the Flk-1 regulatory sequences.
  • One of these lines (2603) showed a complete vascular expression of the reporter gene at E11.5 and was analyzed further (Fig. 11B).
  • Sectioning of ⁇ -galactosidase stained E11.5 transgenic embryos revealed that reporter gene expression was confined to the endothelium of blood vessels, e.g. in the endothelium of the dorsal aorta (Fig. 11D), in venous vessels (Fig. 11 E) and in the perineural vascular plexus and sprouting capillaries invading the neural tube (Fig. 11 F).
  • the lacZ staining pattern of these embryos was compared to heterozygous Flk-1 mutant mouse embryos which express the lacZ gene from the endogenous Flk-1 locus (Shalaby, Nature 376 (1995), 62-66).
  • the lacZ gene was inserted into the endogenous Flk-1 locus via homologous recombination and is therefore expected to reproduce the expression pattern of the endogenous Flk-1 gene (Shalaby, 1995).
  • the lacZ staining pattern of transgenic embryos and the knock-in embryos at E11.5 was indistinguishable (Fig. 11B.C).
  • Example 8 The first intron of the Flk-1 gene contains an autonomous endothelium-specific enhancer
  • tk promoter sequences were amplified from the plasmid ptkSDKIacZ (Schlaeger, 1997) using oligonucleotides tk5' (5'-CCGGTACCCAAACCCCGCCCAGCGTCTTG-3'; SEQ ID NO: 16) and tk3' (5'-CCGACAAGCTTGGTCGCTCGGTGTTCGAGG-3 * ; SEQ ID NO: 17).
  • the PCR product was digested with Kpnl and Hindlll.
  • the lacZ expression pattern of the transgenic mouse line 2603 was further analyzed at various stages of embryonic development and at postnatal days 5 (P5) and 120 (P120).
  • the transcription of lacZ is driven in combination by the -640 bp/+299 bp Flk-1 promoter and the 2.3 kbp BamHI/Xhol intron enhancer fragment.
  • the earliest stage during which transgene expression was detectable by whole mount LacZ staining was in E7.8 embryos (Fig. 13A). This is the earliest stage that was examined.
  • transgene expression was restricted to the vascular endothelium at all stages of embryonic development examined.
  • lacZ staining was detected in vessels of the spleen, kidney, thymus, liver and lung from P5 animals (Fig. 13D-H).
  • lacZ expression was downregulated in most vascular beds of P120 animals, as is the case for the endogenous Flk-1 (Millauer, 1993; Kremer, Cancer Res.
  • Example 10 The 5'-UTR of the Flk-1 gene is required for expression of Flk-1 in the yolk sac vasculature
  • the lacZ gene is under control of all endogenous regulatory elements except for the regions from bp +137 to bp +299 in the 5'-UTR and approximately the first 600 bp of the first intron (Shalaby, 1995). It has been shown in accordance with the present invention that the intron sequences deleted in the knock-in construct created by Shalaby (1995) are not required to generate the strong and complete endothelial-specific reporter gene expression which is mediated by the Flk-1 regulatory sequences described in this study (Fig. 11B and Table III).
  • Primers for PCR analysis were: -258fw: 5'-ATGGTACCCAGGTTGCTGGGGGCAG-3' (SEQ ID NO: 12); LacRev: 5'-TGGTGCCGGAAACCAGGCAAA-3' (SEQ ID NO: 13); LacZPI : 5'- ATCCTCTGCATGGTCAGGTC-3' (SEQ ID NO: 14); LacZP2: 5'- CGTGGCCTGATTCATTCC-3' (SEQ ID NO: 15).
  • the complete vascular staining of the Flk-1 llacZ knock-in embryos at E11.5 indicates that the 5'-UTR is not essential for vascular expression in the embryo proper.
  • the Flk-1 promoter (-640 bpA+299 bp) confers endothelium-specific expression to the firefly luciferase reporter gene in transfected bovine aortic endothelial cells (Ronicke, 1996) and provides for a strong reporter gene transcription in vivo; see Examples 6 to 10. This suggests that transcription factors that are specifically expressed in endothelial cells activate the Flk-1 promoter in a cell-type specific manner.
  • HIF-2 ⁇ The basic helix-loop-helix PAS-domain transcription factor, HIF-2 ⁇ (also known as HLF, HRF or EPAS1), is expressed in endothelial cells during mouse embryonic development (Ema, Proc. Natl. Acad. Sci. USA 94, 4273-4278, 1997; Flamme, Mech. Dev. 63 (1997), 51-60; Tian, Genes Dev. 11 (1997), 72-82) and is thus a candidate to regulate Flk-1 expression. HIF-2 ⁇ has previously been shown to stimulate both the expression of VEGF (Ema, 1997) and Tie2 (Tian, 1997).
  • HIF-2 ⁇ might be involved in the regulation of Flk-1 gene expression
  • A293 cells were co-transfected with a luciferase reporter gene construct containing Flk-1 promoter sequences (-640 bp to +299 bp) and an eukaryotic expression vector that contained the mouse HIF-2 ⁇ cDNA.
  • Mouse HIF-2 ⁇ and HIF-1 ⁇ cDNAs were obtained from a mouse brain capillary endothelial cell cDNA library (Schn ⁇ rch, Development 119 (1993), 957-968) with a 300 bp BamHI/Ncol fragment spanning the 5'UTR of HIF-1 ⁇ .
  • HIF Start (5'-GGGAATTCACCATG AGTTCTGAACGTCGAAAAG-3'; SEQ ID NO: 18) and HIF Flag Stop: (5'- AAGCGGCCGCTCATTTATCGTCATCGTCCTTGTAATCGTTAACTTGATCCAAAG CTCTG-3'; SEQ ID NO: 19).
  • HIF Flag Stop (5'- AAGCGGCCGCTCATTTATCGTCATCGTCCTTGTAATCGTTAACTTGATCCAAAG CTCTG-3'; SEQ ID NO: 19).
  • the PCR product was digested with Eco Rl and Notl and subcloned in the EcoRI and Notl restriction sites of pcDNA3 expression vector.
  • the murine HIF-2 ⁇ cDNA was obtained as described (Flamme, 1997).
  • the phage insert was amplified by PCR using oligonucleotides HRF START (5'- GGGAATTCACCACAATGACAGCTGACAAGGAG-3'; SEQ ID NO: 20) HRF rev (5'- AAGCGGCCGCTCATTTATCGTCATCGTCCTTGTAATCGTTGGTGGCCTGGTCCA GAGCTCTGAG-3"; SEQ ID NO: 21 ) and PCR product was digested with EcoRI/Notl and cloned into the EcoRI and Notl sites of pcDNA3. The sequence encoding the FLAG epitope was included in the reverse oligonucleotide primer.
  • HIF-2 ⁇ and HIF- l ⁇ expression plasmids were constructed by inserting the FLAG-tagged cDNAs into the EcoRI and Notl sites of pcDNA3 (Invitrogen).
  • A293 cells were split 1 :2 into 35 mm dishes and transfected 18 hours later with 4 ⁇ g of DNA (2 ⁇ g o Flk-1 promoter-driven luciferase plasmid, 1 ⁇ g of CMV promoter-driven ⁇ - galactosidase expression plasmid, and 1 ⁇ g of the HIF-2 ⁇ or HIF-1 ⁇ expression plasmids, or pBluescript SKII and pcDNA3 as a control) using a transfection kit (MBS, Stratagene).
  • reporter gene activity measurements were performed using the Dual Light Kit (Tropix, Bedford, MA).
  • the luciferase activity of each extract was normalized to the respective ⁇ -galactosidase activity. Endogenous background levels of both enzyme activities were measured using extracts from mock-transfected cells and were substracted.
  • the normalized luciferase activity of the control transfection was arbitrarily set to 1. Each value represents the average of at least six experiments.
  • HIF-2 ⁇ In comparison to cells transfected with the luciferase reporter construct alone, co- transfection of the HIF-2 ⁇ construct increased reporter gene activity approximately 15-fold (Fig. 15). In contrast, HIF-1 ⁇ , a close relative of HIF-2 which stimulates the hypoxia-induced transcription of the VEGF gene, failed to stimulate the reporter construct (Fig. 15). These results suggest that HIF-2 ⁇ regulates the expression of the Flk-1 gene.
  • the mouse Flk-1 receptor is crucial for the differentiation of the hemangioblastic lineage and during embryonic vascular development (Risau, Annu. Rev. Cell Dev. Biol. 11 (1995), 73-91 ; Shalaby, 1995; Risau, 1997). Moreover, Flk-1 plays a central role in the regulation of neovascularization in a wide variety of tumors (Plate, Brain Pathol. 4 (1994) , 207-218; Ferrara, 1996). To elucidate the basis of its endothelial expression, regulatory sequences of the murine Flk-1 gene have been isolated and characterized that confer endothelium-specific reporter gene expression in transgenic mouse embryos. Transgene expression driven by these sequences was strong, specific, and highly reproducible.
  • Reproducible endothelium-specific expression was therefore dependent on sequences from the first intron. These sequences also activated the heterologous tk promoter specifically in endothelial cells in vivo, and were active in an orientation independent manner. Thus, they fulfill the criteria for an autonomous tissue specific enhancer.
  • the intron sequences that were sufficient for endothelium-specific expression were contained in a 510 bp fragment.
  • Several potential binding sites for known transcription factors could be identified therein (see Figure 12), including consensus binding sites for c-ets1 , PEA3 (an Ets-like transcription factor), GATA transcription factors, and Scl/Tal-1.
  • the c-ets1 transcription factor was proposed to be involved in the early differentiation of endothelial cells from their precursors (Pardanaut, Cell Adhesion and Communication 1 (1993), 151-160).
  • c-ets1 is expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans (Wernert, Am. J. Pathol.
  • GATA-2 is expressed in both the endothelial and hematopoietic lineages (Elefanty, Blood 90 (1997), 1435-1447). Scl/Tal-1 has recently been implicated in the regulation of Flk-1 expression in Zebrafish (Liao, Genes Dev.
  • the intronic 303 bp Tie2 core enhancer also contains potential binding sites for transcription factors of the Ets and GATA families (Schlaeger, 1997), and c-ets1 or PEA3 binding sites are present in the promoters of Tie1, Tie! and Flt-1 (Korhonen, 1995; Schlaeger, 1995; Wakiya, J. Biol. Chem. 271 (1996), 30823-30828).
  • the Flk-1 5'-UTR has been shown to contain a positive acting, endothelial cell-specific element between nucleotides +136 and +299 (Ronicke, 1996).
  • the complete vascular staining of the Flk-1 llacZ knock-in embryo proper at E11.5 demonstrates that the 5'-UTR is not essential for intraembryonic vascular expression at this developmental stage.
  • HIF-2 ⁇ in the regulation of Flk-1 expression further emphasizes the role of basic helix-loop-helix/PAS-domain transcription factors in the regulation of components of the VEGF signal transduction system and of vascular development.
  • the upregulation of VEGF in response to hypoxia is generally thought to be mediated by HIF-1.
  • mouse embryos lacking functional genes for HIF-1 ⁇ or ARNT show defects in vascular development, perhaps due to reduced VEGF levels (Maltepe, Nature 386 (1997), 403-407; Iyer, Genes Dev. 12 (1998), 149-162). This observation indicates that the physiological relevance of these transcription factors is not restricted to adaptation to hypoxia, but extends to the regulation of normal vascular development.
  • HIF-2 ⁇ is expressed in various tissues, including the developing endothelium of several organs, for example in the brain (Flamme, 1997). It seems therefore likely that HIF-2 ⁇ is involved in the regulation of Flk-1 expression in blood vessels that co-express HIF-2 and Flk-1. Interestingly, HIF-2 ⁇ is also expressed in tissues that express the Flk-1 receptor ligand, VEGF, and has been shown to stimulate VEGF expression (Ema, 1997). Taken together, these observations support the hypothesis that HIF-2 ⁇ is both an intrinsic and extrinsic regulator of blood vessel growth and function (Flamme, 1997), by stimulating both receptor and ligand expression. The expression of VEGF and Flk-1 shows a remarkable coordinate temporal pattern both in development and in tumors.
  • VEGF and Flk-1 are expressed transiently in the developing mouse brain, and are largely down-regulated in the adult, but reactivated in brain tumors (Plate, 1994).
  • both the VEGF and Flk-1 expression are highly up-regulated, and this correlates with the up-regulation of HIF-2 expression in the stromal cells of this tumor type.
  • HIF-2 ⁇ contributes to the remarkably coordinated expression of VEGF and Flk-1 in other tumor types, remains to be established, since for example in glioblastomas - another cerebral tumor - up-regulation of VEGF is due to hypoxia, and HIF-2 ⁇ is inducible by hypoxia.
  • Flk-1 expression is not directly stimulated by hypoxia (Gerber, J. Biol. Chem. 272 (1997), 23659-23; Kremer, 1997).
  • hypoxia a hypoxia response
  • Flk-1 is the only receptor whose function is required for the determination of the endothelial lineage. Therefore, the Flk-1 gene represents the ideal candidate for studying the transcriptional regulatory mechanisms that are active during the emergence of the endothelial lineage. The observation that the isolated regulatory elements of the Flk-1 gene are active in early stage vascular development are of great importance for this objective.
  • Flk-1 gene regulatory sequences is also of great potential relevance in the therapy of certain diseases.
  • the Flk-1 receptor has been demonstrated to be a key regulator of angiogenesis in various diseases, including cancer (Plate, 1994). Therefore, the study of the regulatory elements involved in the upregulation of Flk-1 expression in the tumor endothelium appears to be particularly relevant for studying the mechanisms of tumor angiogenesis. Further studies will unravel whether the same regulatory elements of the Flk-1 gene that confer endothelium-specific expression in mouse embryos are also active in the tumor vasculature.
  • Flk-1 gene regulatory elements active in the tumor vasculature may provide information about the signaling pathways that can be targeted for anti-angiogenic tumor therapy.
  • the Flk-1 gene regulatory elements will be useful for targeting expression of genes to the vasculature.
  • An attractive possibility is the expression of suicide genes (Ozaki, Hum. Gene Ther. 7 (1996), 1483-1490) under the control of these elements.
  • the use of the Flk-1 gene regulatory elements in combination with, e.g., the Cre/loxP system may provide a powerful tool for specifically inactivating genes in the developing vasculature or in tumor endothelium.
  • the present invention is not to be limited in scope by its specific embodiments described which are intended as single illustrations of individual aspects of the invention and any DNA molecules, or vectors which are functionally equivalent are within the scope of the invention. Indeed, various modifications of the invention in addition to those shown and described therein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Said modifications intended to fall within the scope of the appended claims.
  • MOLECULE TYPE DNA (genomic)
  • HYPOTHETICAL NO
  • ACACTAGCAA TACGGGCTGA ATCTGACCTA ATCTCTGCTG TTGAAAATTT TGCCTAGCCT 540
  • TCTTACCCCT CCCCATCTCT CCTTCACCTC TGAGAAGGGG GGATACCTCC TGTCTTATCT 900
  • TTTCATACAC CTTACTTATT CTATTCATTT TTCAGGAAGG CATGTTTAAT GTTTTTTTTT 1020
  • CAGAAACTTA AGAAAACACT TACACGAAGC AAACATGGGG AAGTGCCATG CAAGCATGTG 4020
  • TCCCTCTACC CAGATCTGAC AGCCCTCCTT GGCTCTTTTG CTGAGGTTTG TTTGAGTTTG 5040
  • CTCTTAGCTA AGAGGCCACA CACCCAGGGG GAACACCGAT AAAAAGAACA AGCCAGAACC 5160
  • TGCCCACACC AAACATGCCC AAGATCTTCA AGTATAATTT TATTATATAG ATTCGCTATG 5340 TGTTGACATG TTTTTATAGT GAACCTGGAT TTTACAAACC CTCCTGGTTT GCCACCTGCT 5400
  • GCAAGTGTCT CAGAGCCCAT TACTGGCTAC ATTTTACTTC CACCAGAAAC CGAGCTGCGT 6480
  • CTTCCCTTCC CTTCCCTTCC CTTCCCTTCC CTTCCCTTTC CCTCTTCCTT TTCCTCCTCC 7860
  • CAGCCTGGAA CATGTGCTTG CCCTGGGTTC CATAGAGAAG CAAGTTGCTT TAAAGCCCAG 8220
  • GCTCCCGTCC CTTTCAGGGG TATGGAGACG AGCTGTAGAG AGATGTCTCC AGGGAGTTTT 10260 CATTAATCAG CAATTTAGTC AGATCTGTGC ATCCTATGCT TTACAAGAAA TGTCAGTGGG 10320
  • ACATACTGAC AATTTTGGCA AATACAACCC TTCAGATTAC TTGCAGGTAA GGATTCCTTT 10740
  • GTCTGTCTCC TTATATTAGT GATAGGTTCC AGAAAGGCAC TGATTTTTTT TCTTCCCTGG 12300

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Husbandry (AREA)
  • Cardiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP98934910A 1997-06-03 1998-06-03 Regulatorische sequenzen für die in-vivo-expression einer heterologen dns-sequenz in endothelzellen und ihre verwendungen. Expired - Lifetime EP1007714B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP98934910A EP1007714B1 (de) 1997-06-03 1998-06-03 Regulatorische sequenzen für die in-vivo-expression einer heterologen dns-sequenz in endothelzellen und ihre verwendungen.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97108959 1997-06-03
EP97108959 1997-06-03
PCT/EP1998/003318 WO1998055638A1 (en) 1997-06-03 1998-06-03 Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof
EP98934910A EP1007714B1 (de) 1997-06-03 1998-06-03 Regulatorische sequenzen für die in-vivo-expression einer heterologen dns-sequenz in endothelzellen und ihre verwendungen.

Publications (2)

Publication Number Publication Date
EP1007714A1 true EP1007714A1 (de) 2000-06-14
EP1007714B1 EP1007714B1 (de) 2005-12-14

Family

ID=8226873

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98934910A Expired - Lifetime EP1007714B1 (de) 1997-06-03 1998-06-03 Regulatorische sequenzen für die in-vivo-expression einer heterologen dns-sequenz in endothelzellen und ihre verwendungen.

Country Status (7)

Country Link
US (2) US7011973B1 (de)
EP (1) EP1007714B1 (de)
JP (1) JP2002511750A (de)
AT (1) ATE312935T1 (de)
AU (1) AU8435698A (de)
DE (1) DE69832798T2 (de)
WO (1) WO1998055638A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
US6867348B1 (en) * 1999-12-16 2005-03-15 Xenogen Corporation Methods and compositions for screening for angiogenesis modulating compounds
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
WO2005113596A2 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
PT1804835E (pt) 2004-09-13 2010-10-04 Genzyme Corp Construções multiméricas
PL2601214T3 (pl) 2010-08-06 2018-05-30 Genzyme Corporation Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
US9976143B2 (en) 2014-10-03 2018-05-22 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
CA3000971A1 (en) 2015-10-09 2017-04-13 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
SG11201804443UA (en) 2015-12-14 2018-06-28 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
PL3673080T3 (pl) 2017-08-25 2024-03-11 Stoke Therapeutics, Inc. Oligomery antysensowne do leczenia stanów i chorób
MX2020011695A (es) 2018-05-04 2021-02-26 Stoke Therapeutics Inc Métodos y composiciones para el tratamiento de la enfermedad por almacenamiento de éster de colesterilo.
KR20230022409A (ko) 2020-05-11 2023-02-15 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 opa1 안티센스 올리고머

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916763A (en) * 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9855638A1 *

Also Published As

Publication number Publication date
AU8435698A (en) 1998-12-21
JP2002511750A (ja) 2002-04-16
ATE312935T1 (de) 2005-12-15
WO1998055638A9 (en) 1999-04-08
DE69832798T2 (de) 2006-09-14
US20050235367A1 (en) 2005-10-20
WO1998055638A1 (en) 1998-12-10
DE69832798D1 (de) 2006-01-19
EP1007714B1 (de) 2005-12-14
US7011973B1 (en) 2006-03-14

Similar Documents

Publication Publication Date Title
Okuno et al. Potential autoregulation of transcription factor PU. 1 by an upstream regulatory element
Khandekar et al. A Gata2 intronic enhancer confers its pan-endothelia-specific regulation
Kappel et al. Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice
Sasaki et al. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta.
EP1007714B1 (de) Regulatorische sequenzen für die in-vivo-expression einer heterologen dns-sequenz in endothelzellen und ihre verwendungen.
Moessler et al. The SM 22 promoter directs tissue-specific expression in arterial but not in venous or visceral smooth muscle cells in transgenic mice
Korhonen et al. Endothelial-specific gene expression directed by the tie gene promoter in vivo
Tybulewicz et al. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene
Tse et al. Null mutation of the Lmo4 gene or a combined null mutation of the Lmo1/Lmo3 genes causes perinatal lethality, and Lmo4 controls neural tube development in mice
Biben et al. Developmental and Tissue-Specific Regulation of the Murine Cardiac Actin Genein VivoDepends on Distinct Skeletal and Cardiac Muscle-Specific Enhancer Elements in Addition to the Proximal Promoter
US5583009A (en) Method of preparing recombinant proteins in transgenic animals containing metallothionein gene elements that bestow tissue-independent copy number-dependent, position-indepedent gene expression
CA2598859C (en) Transgenic animal as a model for fibrotic diseases
Yamamoto et al. Upstream and downstream of erythroid transcription factor GATA‐1
WO1998056936A9 (en) Regulatory sequences involved in hypoxia regulated gene expression and uses thereof
Minami et al. Differential regulation of the von Willebrand factor and Flt-1 promoters in the endothelium of hypoxanthine phosphoribosyltransferase–targeted mice
Jin et al. Targeted deletion of Hsf1, 2, and 4 genes in mice
Boutet et al. Identification of an octamer element required for in vivo expression of the TIE1 gene in endothelial cells
Jin et al. Targeted deletion of Hsf1, 2, and 4 genes in mice
JP4811765B2 (ja) 外来遺伝子の誘導発現の制御が可能な発現ベクター
AU3672697A (en) The butyrophilin gene promoter and uses thereof
Moreau-Gachelin et al. Potential Autoregulation of Transcription
US7109295B2 (en) Zinc finger-based drug-dependent gene regulation system
Shishima Characterization of the promoter of flk2, a gene encoding a receptor tyrosine kinase involved in hematopoiesis
JPH0779773A (ja) 癌細胞株
Elnitski et al. A Negative Cis-element Regulates the Level of Enhancement by Hypersensitive Site 2 of the ß-Globin Locus Control Region

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KAPPEL, ANDREAS

Inventor name: ROENICKE, VOLKER

Inventor name: RISAU, WERNER

Inventor name: BREIER, GEORG

17Q First examination report despatched

Effective date: 20030804

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051214

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20051214

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051214

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNGDER WISSENSC

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69832798

Country of ref document: DE

Date of ref document: 20060119

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060314

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060314

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060314

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060325

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: VOSSIUS & PARTNER

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060515

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060630

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20060915

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: VOSSIUS & PARTNER;NADELBERG 3;4051 BASEL (CH)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051214

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20090616

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20090608

Year of fee payment: 12

Ref country code: AT

Payment date: 20090616

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20090612

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20090611

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20090609

Year of fee payment: 12

Ref country code: DE

Payment date: 20090730

Year of fee payment: 12

BERE Be: lapsed

Owner name: *MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENS

Effective date: 20100630

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20100603

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20110228

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100630

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100603

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100630

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100630

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100603